文献速递胸部肿瘤

晚期非小细胞肺癌肿瘤组织与配对循环肿瘤DNA中EGFR突变状态不一致性的综合分析

Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2017-05-26

本研究纳入2463例具有配对肿瘤组织与循环肿瘤DNA(ctDNA)标本的患者,用ARMS法检测EGFR突变,对1017例携带突变者中472例接受EGFR酪氨酸激酶抑制剂治疗者的三个不一致组进行分析。结果显示三组中位无进展生存期相似(p=0.062),ddPCR和二代测序复核发现组B中27例实际携带EGFR突变、组C中64例ctDNA复核阳性。结论认为瘤内异质性和ARMS法灵敏度相对较低导致不一致,ctDNA→组织补充模式可能是合理的临床检测流程。

要点

  • 2463例配对标本中1017例经ARMS检出EGFR突变,其中472例接受EGFR TKI治疗。
  • 三组接受EGFR TKI患者的中位无进展生存期相似(p=0.062)。
  • ddPCR和二代测序复核发现组B中27例、组C中64例实际携带EGFR突变。

核心结论

  • 瘤内异质性和ARMS法相对较低的灵敏度是肿瘤组织与ctDNA之间EGFR突变状态不一致的原因。
  • ctDNA→TT模式可能是确定EGFR突变状态的合理临床流程。

研究设计与样本

  • 研究纳入2463例具有配对肿瘤组织和ctDNA标本、经ARMS法检测EGFR突变状态并接受EGFR TKI治疗的患者,分为三组:A组肿瘤组织阳性/ctDNA阳性,B组肿瘤组织阴性/ctDNA阳性,C组肿瘤组织阳性/ctDNA阴性。
  • 对EGFR突变状态不一致的患者采用微滴数字PCR(ddPCR)和二代测序复核,同时对手术肿瘤标本进行显微切割后以ddPCR检测EGFR突变。

主要发现

  • 2463例配对标本中1017例经ARMS在肿瘤组织和/或ctDNA中检出EGFR突变,其中472例接受EGFR TKI治疗,A、B、C组分别为264例、28例、180例。
  • 三组接受EGFR TKI患者的中位无进展生存期相似(p=0.062)。
  • 对活检标本(n=22)和显微切割手术标本(n=5)行ddPCR和二代测序,发现B组中27例携带EGFR突变。
  • 经ddPCR复核,C组中64例患者ctDNA检测EGFR突变阳性。
  • ctDNA→TT模式与TT→ctDNA模式检测效率相似,且节省约30%的肿瘤组织。

临床怎么用

  • 作者认为ctDNA→TT模式可能是确定EGFR突变状态的合理临床流程。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study aimed to address the underlying reasons for and clinical significance of the discordant EGFR mutation (EGFRm) status between tumor tissue (TT) and circulating tumor DNA (ctDNA). METHODS: Three groups of EGFR tyrosine kinase inhibitor (EGFR TKI)-treated patients whose EGFRm status was determined by the amplification refractory mutation system (ARMS) were included (group A, TT-positive/ctDNA-positive EGFRm status; group B, TT-negative/ctDNA-positive EGFRm status; and group C, TT-positive/ctDNA-negative EGFRm status). Patients with discordant EGFRm status were reevaluated by droplet digital polymerase chain reaction (ddPCR) and next-generation sequencing. Meanwhile, surgical tumor specimens were microdissected for EGFRm detection by ddPCR. RESULTS: Of the 2463 patients with matched TT and ctDNA specimens, 1017 patients carried EGFRm in TT and/or ctDNA by the ARMS. Of these 1017 patients, 472 received EGFR TKIs, including 264, 28, and 180 in groups A, B, and C, respectively. The median progression-free survivals of those receiving EGFR TKIs across the three groups were similar (p = 0.062). Through ddPCR and next-generation sequencing of biopsy specimens (n = 22) and microdissected surgical specimens (n = 5), 27 patients in group B were identified as harboring EGFRm. After reevaluation by ddPCR, 64 patients in group C tested positive for EGFRm in their ctDNA. ctDNA as a screen for EGFRm then tissues as supplement (ctDNA→TT pattern) had similar detection efficiency and saved about 30% of TT compared with TT for initial EGFRm detection followed by ctDNA (TT→ctDNA pattern). CONCLUSIONS: Intratumor heterogeneity and the relatively low sensitivity of the ARMS contributed to discordant EGFRm status between TT specimens and ctDNA. The ctDNA→TT pattern might be a rational clinical procedure for EGFRm determination.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Wan R, Wang Z, Lee JJ, et al. Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 28552765. doi:10.1016/j.jtho.2017.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。